Who
Michael A. Klobuchar
Director
Company insider
Files Form 4 as: Director, Revvity; Chief Operating Officer, Eikon Therapeutics; EVP - Chief Strategy Officer, Merck & Company.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 24 Feb 2022
- Last trade
- 7 May 2026
- Last filed
- 11 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,157 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,157 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,074 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,338 at $0.00 | filing |
| 4 May 2024filed 6 May 2024 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —887 at $0.00 | filing |
| 4 May 2024filed 6 May 2024 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $113K887 at $127.51 | filing |
| 4 May 2024filed 6 May 2024 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $56K437 at $127.51 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —977 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,218 at $0.00 | filing |
| 30 Apr 2024filed 2 May 2024 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,508 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —217 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —264 at $0.00 | filing |
| 22 Jan 2024filed 24 Jan 2024 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code A | $465K3,896 at $119.43 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —885 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $105K885 at $118.22 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $52K436 at $118.22 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.